Arch Therapeutics to Present AC5® Advanced Wound System at the 2024 Symposium on Advanced Wound Care Fall Meeting (SAWC Fall)
Arch Therapeutics (OTCQB: ARTH) will showcase its AC5® Advanced Wound System at the 2024 Symposium on Advanced Wound Care Fall Meeting (SAWC Fall) in Las Vegas from October 2-5, 2024. The company aims to educate clinicians about AC5, present case studies, and continue strategic meetings with wound care companies.
AC5 is a self-assembling wound care product cleared by the FDA for managing partial and full-thickness wounds. Two clinical cases demonstrating AC5's effectiveness will be presented during the poster viewing session on October 4, 2024:
- Management of tunneling wounds using synthetic self-assembling peptide matrix
- A pilot study on lower extremity wounds utilizing a novel nanoparticle self-assembling peptide
Arch Therapeutics' CEO, Terrence W. Norchi, MD, highlighted AC5's potential importance in addressing the needs of over 6 million people with non-healing wounds in the US alone.
Arch Therapeutics (OTCQB: ARTH) presenterà il suo AC5® Advanced Wound System al Simposio 2024 sulla Cura Avanzata delle Ferite - Incontro Autunnale (SAWC Fall) che si terrà a Las Vegas dal 2 al 5 ottobre 2024. L'azienda si propone di formare i clinici su AC5, presentare casi di studio e proseguire incontri strategici con aziende esperte nella cura delle ferite.
AC5 è un prodotto per la cura delle ferite auto-assemblante approvato dalla FDA per la gestione di ferite parziali e a tutto spessore. Durante la sessione di visualizzazione dei poster del 4 ottobre 2024 saranno presentati due casi clinici che dimostrano l'efficacia di AC5:
- Gestione delle ferite tunnelizzate utilizzando una matrice peptidica sintetica auto-assemblante
- Uno studio pilota sulle ferite degli arti inferiori che utilizza un nuovo peptide auto-assemblante a nanoparticelle
Il CEO di Arch Therapeutics, Terrence W. Norchi, MD, ha sottolineato l'importanza potenziale di AC5 nell'affrontare le esigenze di oltre 6 milioni di persone con ferite non cicatrizzanti solo negli Stati Uniti.
Arch Therapeutics (OTCQB: ARTH) presentará su AC5® Advanced Wound System en el Simposio 2024 sobre Cuidado Avanzado de Heridas - Reunión de Otoño (SAWC Fall) en Las Vegas del 2 al 5 de octubre de 2024. La empresa tiene como objetivo educar a los clínicos sobre AC5, presentar estudios de caso y continuar reuniones estratégicas con empresas de cuidado de heridas.
AC5 es un producto de cuidado de heridas autoensamblante aprobado por la FDA para el manejo de heridas parciales y de grosor completo. Durante la sesión de visualización de carteles del 4 de octubre de 2024 se presentarán dos casos clínicos que demuestran la efectividad de AC5:
- Manejo de heridas en túneles utilizando una matriz de péptido sintético autoensamblante
- Un estudio piloto sobre heridas de extremidades inferiores utilizando un nuevo péptido autoensamblante a base de nanopartículas
El CEO de Arch Therapeutics, Terrence W. Norchi, MD, destacó la importancia potencial de AC5 para abordar las necesidades de más de 6 millones de personas con heridas que no cicatrizan solo en los Estados Unidos.
Arch Therapeutics (OTCQB: ARTH)는 2024년 10월 2일부터 5일까지 라스베이거스에서 열리는 2024 고급 상처 관리 심포지엄 가을 회의 (SAWC Fall)에서 AC5® 고급 상처 시스템을 선보일 예정입니다. 이 회사는 AC5에 대해 임상의들에게 교육하고 사례 연구를 발표하며 상처 치료 회사들과 전략적인 회의를 계속하고자 합니다.
AC5는 FDA에 의해 부분적 및 전체 두께의 상처 관리를 위해 승인된 자가 조립식 상처 치료 제품입니다. 2024년 10월 4일 포스터 발표 세션에서 AC5의 효과를 보여주는 두 가지 임상 사례가 발표될 예정입니다:
- 합성 자가 조립 펩타이드 매트릭스를 이용한 터널 상처 관리
- 혁신적인 나노입자 자가 조립 펩타이드를 이용한 하반신 상처에 대한 파일럿 연구
Arch Therapeutics의 CEO Terrence W. Norchi, MD는 AC5가 미국에서만 600만 명이 넘는 비치유성 상처 환자들의 요구를 해결하는 데 있어 중요한 역할을 할 가능성이 있음을 강조했습니다.
Arch Therapeutics (OTCQB: ARTH) présentera son AC5® Advanced Wound System lors du Symposium 2024 sur la Soins Avancés des Plaies - Réunion d'Automne (SAWC Fall) à Las Vegas du 2 au 5 octobre 2024. L'entreprise vise à éduquer les cliniciens sur AC5, à présenter des études de cas et à poursuivre des réunions stratégiques avec des entreprises de soins des plaies.
AC5 est un produit de soins des plaies auto-assemblant approuvé par la FDA pour la gestion des plaies partielles et à épaisseur totale. Deux cas cliniques démontrant l'efficacité d'AC5 seront présentés lors de la session de visualisation des affiches le 4 octobre 2024 :
- Gestion des blessures tunnelisées utilisant une matrice peptidique synthétique auto-assemblante
- Une étude pilote sur les plaies des membres inférieurs utilisant un nouveau peptide auto-assemblant à nanoparticules
Le PDG d'Arch Therapeutics, Terrence W. Norchi, MD, a souligné l'importance potentielle d'AC5 pour répondre aux besoins de plus de 6 millions de personnes avec des plaies non cicatrisantes rien qu'aux États-Unis.
Arch Therapeutics (OTCQB: ARTH) wird sein AC5® Advanced Wound System auf dem 2024 Symposium für fortgeschrittene Wundversorgung Herbsttagung (SAWC Fall) in Las Vegas vom 2. bis 5. Oktober 2024 präsentieren. Das Unternehmen hat sich zum Ziel gesetzt, Kliniker über AC5 zu informieren, Fallstudien vorzustellen und strategische Gespräche mit Unternehmen im Bereich Wundversorgung fortzusetzen.
AC5 ist ein von der FDA zugelassenes selbstorganisierendes Wundpflegeprodukt zur Behandlung von teilweise und vollständig durchdringenden Wunden. Während der Poster-Präsentationssitzung am 4. Oktober 2024 werden zwei klinische Fälle vorgestellt, die die Wirksamkeit von AC5 demonstrieren:
- Management von tunnellierenden Wunden mit einer synthetischen selbstorganisierenden Peptidmatrix
- Eine Pilotstudie zu Wunden der unteren Extremitäten unter Verwendung eines neuartigen selbstorganisierenden Peptids auf Nanopartikelbasis
Der CEO von Arch Therapeutics, Terrence W. Norchi, MD, hob die potenzielle Bedeutung von AC5 zur Deckung der Bedürfnisse von über 6 Millionen Menschen mit nicht heilenden Wunden allein in den USA hervor.
- None.
- None.
SAWC Fall provides a venue to educate clinicians about AC5 Advanced Wound System, present case studies, and continue strategic meetings with wound care companies.
FRAMINGHAM, Mass., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical products, today announced that the Company’s commercial product, AC5® Advanced Wound System (“AC5”), will be featured at the 2024 Symposium on Advanced Wound Care Fall Meeting (“SAWC Fall”), which takes place at Caesars Palace, Las Vegas, from October 2-5, 2024.
SAWC participants include doctors, nurses, and members of industry. Arch’s team will demonstrate AC5 Advanced Wound System at our booth (#334) in the main exhibit hall and elsewhere during the conference.
Another purpose of our participation in SAWC is to continue ongoing meetings with wound care and other life science companies that are interested in Arch’s patented wound care products and novel approach to wound healing.
Terrence W. Norchi, MD, President and CEO of Arch Therapeutics, said, “AC5 is a new and easy-to-use option for many doctors who treat patients in the operating room or in their office. With its self-assembly mechanism of action, AC5 provides a differentiated approach to the management of both acute surgical and chronic wounds. The potential importance of AC5 is underscored by the sheer number of people with non-healing wounds, thought to exceed 6 million in the US alone.”
On Friday, October 4, 2024, the following clinical cases, which further demonstrates the use of AC5 in patients with challenging wounds, will be presented during the poster viewing session:
Successful Management of Tunneling Wounds with the use of Synthetic Self-assembling Peptide Matrix.
By Dr. Misael C. Alonso, MD, FACP, CWSP, FAPWCA
Poster #C-007
A Pilot Study of Lower Extremity Wounds Utilizing a Novel Nanoparticle Self-Assembling Peptide.
by Eric J. Lullove, DPM, CWSP, DABLES, FAPWH(c), FFPM, RCPS (Glasg)
Poster #: CR-032
Norchi continued, “The clinical information presented at SAWC includes a pilot study that assesses healing time and potential cost savings when AC5 is used on complicated post-operative non-healing wounds as well as a case study that assesses management of a tunneling wound with AC5. These clinical scenarios add to the growing clinical experience with AC5 in wounds that are challenging for both patients and many currently available wound modalities.”
AC5 is cleared by the Food and Drug Administration for the management of partial and full-thickness wounds, such as pressure sores, leg ulcers, diabetic ulcers, and surgical wounds. AC5 is a synthetic self-assembling wound care product that provides clinicians with multi-modal support and utility across all phases of wound healing. Additional information may be found here: https://www.archtherapeutics.com/technology/clinical-data.
About Arch Therapeutics, Inc.
Arch Therapeutics, Inc. is a biotechnology company developing a novel approach to stop bleeding (hemostasis), control leaking (sealant) and manage wounds during surgery, trauma and interventional care. Arch is developing products based on an innovative self-assembling barrier technology platform with the goal of making care faster and safer for patients. Arch has received regulatory authorization to market AC5® Advanced Wound System and AC5® Topical Hemostat as medical devices in the United States and Europe, respectively. Arch's development stage product candidates include AC5-G™, AC5-V® and AC5® Surgical Hemostat, among others.1,2
About SAWC
The Symposium on Advanced Wound Care meeting (“SAWC”) serves as a forum to connect the entire wound care team—physicians, podiatrists, nurses, physical therapists, researchers, scientists, and dietitians—with the foremost experts in wound care to improve patient outcomes through education. No other wound care conference offers the level of education, advanced state-of-the-art clinical reviews, and emerging research findings.
Notice Regarding Forward-Looking Statements
This news release contains “forward-looking statements” as that term is defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the Uplisting, the Uplisting transaction, the intended use of net proceeds from the private placement, references to novel technologies and methods, our business and product development plans and projections, or market information. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with developing new products or technologies and operating as a development stage company, our ability to retain important members of our management team and attract other qualified personnel, our ability to raise the additional funding we will need to continue to pursue our business and product development plans, our ability to obtain required regulatory approvals, our ability to produce commercial quantities of our products within projected timeframes, our ability to develop and commercialize products based on our technology platform, and market conditions, and our ability to establish additional commercialization partnerships and build a critical mass of field sales representatives. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in the reports and other documents we file with the SEC, available at www.sec.gov.
1 AC5-G, AC5-V, and AC5 Surgical Hemostat are currently investigational devices limited by law to investigational use.
2 AC5, AC5-G, AC5-V and associated logos are trademarks and/or registered trademarks of Arch Therapeutics, Inc. and/or its subsidiaries.
Contact:
ARTH Investor Relations
Toll Free: +1-855-340-ARTH (2784) (US and Canada)
Email: investors@archtherapeutics.com
Website: www.archtherapeutics.com
or
Michael Abrams
Chief Financial Officer
Arch Therapeutics, Inc.
Phone: 617-680-7841
FAQ
When and where is Arch Therapeutics presenting AC5 Advanced Wound System at SAWC Fall 2024?
What clinical cases related to AC5 Advanced Wound System will be presented at SAWC Fall 2024?
What is the FDA clearance status of Arch Therapeutics' AC5 Advanced Wound System (ARTH)?
How many people in the US are estimated to have non-healing wounds, according to Arch Therapeutics (ARTH)?
